ATM loss in non-small cell lung cancer: Therapeutic implications for platinum-based therapies

Simple item page
atmire.migration.oldid5907
dc.contributor.advisorBebb, Gwyn
dc.contributor.advisorLees-Miller, Susan
dc.contributor.authorMoore, Jarrett
dc.contributor.committeememberJirik, Frank
dc.contributor.committeememberCobb, Jennifer
dc.date.accessioned2017-08-31T15:06:33Z
dc.date.available2017-08-31T15:06:33Z
dc.date.issued2017
dc.date.submitted2017en
dc.description.abstractTherapeutic strategies for non-small cell lung cancer (NSCLC), such as platinum-based antineoplastic therapies (platins), generate DNA breaks and stimulate DNA damage response pathways. A key component of the response to DNA damage is the protein ataxia telangiectasia mutated (ATM). Evidence from the Glans-Look Database suggests that patients with low tumour ATM protein expression have improved disease-free survival rates after adjuvant platin therapy. I hypothesize that ATM-deficient tumours will be innately sensitive to platin therapies. NSCLC cell lines were treated with increasing concentrations of platins and assessed for ATM activation. ATM knockdown cell lines were generated using shRNA and investigated for cisplatin sensitivity. ATM-proficient cell lines demonstrated increased levels of phosphorylated-ATM in response to platins. ATM knockdowns had increased sensitivity to IR and a trend toward increased sensitivity to cisplatin. It is evident that platin exposure induced an ATM mediated signaling, however the predictive capabilities for ATM-loss to platin sensitivity is still unclear.en_US
dc.identifier.citationMoore, J. (2017). ATM loss in non-small cell lung cancer: Therapeutic implications for platinum-based therapies (Master's thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca. doi:10.11575/PRISM/25058en_US
dc.identifier.doihttp://dx.doi.org/10.11575/PRISM/25058
dc.identifier.urihttp://hdl.handle.net/11023/4053
dc.language.isoeng
dc.publisher.facultyGraduate Studies
dc.publisher.institutionUniversity of Calgaryen
dc.publisher.placeCalgaryen
dc.rightsUniversity of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission.
dc.subjectOncology
dc.subject.othernon-small cell lung cancer
dc.subject.otherataxia telangiectasia mutated
dc.titleATM loss in non-small cell lung cancer: Therapeutic implications for platinum-based therapies
dc.typemaster thesis
thesis.degree.disciplineMedical Science
thesis.degree.grantorUniversity of Calgary
thesis.degree.nameMaster of Science (MSc)
ucalgary.item.requestcopytrue
Files
Collections
Open Theses and Dissertations